Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

(VOLC, PWRM.OB) - Watch List for Thursday Nov. 4, 2010

|Includes: Volcano Corporation (VOLC)




volc   VOLC, Volcano Corporation

VOLC develops, manufactures, and commercializes a suite of intravascular ultrasound (IVUS) and functional measurement (NYSEARCA:FM) products used in the diagnosis and treatment of vascular and structural heart disease.

VOLC's IVUS products consist of consoles, digital and rotational IVUS catheters, and imaging tools, including virtual histology, IVUS tissue characterization, and ChromaFlo stent apposition analysis; and FM offerings include consoles and single-use pressure and flow guide wires used to measure the pressure and flow characteristics of blood enabling physicians to gauge the plaque?s physiological impact on blood flow and pressure.

** VOLC reported that revenues in the third quarter of 2010 increased 35 percent over revenues in the same period a year ago.

VOLC's profitability on a GAAP basis improved $9.6 million year-over-year as it reported net income of $5.6 million in the third quarter of 2010.

More about VOLC at


PWRM, Power3 Medical Products, Inc., PWRM.OB

PWRM is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease).

PWRM recently reported that it has signed a definitive agreement to acquire all of the stock of Rozetta-Cell Life Sciences, a medical biotechnology company that focuses on the delivery and imaging of stem cells during therapy. Rozetta-Cell has a robust intellectual property portfolio and has created numerous products for adult stem cell therapy that are ready for market globally.

** According to PWRM’s President and Chief Scientific Officer, with the addition of Rozetta-Cell, PWRM will significantly strengthen its IP portfolio in a major growth market by merging regenerative medicine with the technologies that the company is using to identify disease-specific protein biomarkers and develop them into screening and diagnostic tests to address unmet medical needs.

Completion of the merger is subject to customary closing conditions, including receipt by the parties of all necessary board and shareholder approvals and third party consents. There can be no assurance that these conditions will be met or that the merger will be completed.

More about PWRM at


Signup for FREE Daily Stock Alerts From


Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services from Power 3 Medical Products Inc. (OTC:PWRM)